KR101058290B1 - 면역글로불린 단편을 이용한 인슐린분비 펩타이드 약물결합체 - Google Patents

면역글로불린 단편을 이용한 인슐린분비 펩타이드 약물결합체 Download PDF

Info

Publication number
KR101058290B1
KR101058290B1 KR1020080001479A KR20080001479A KR101058290B1 KR 101058290 B1 KR101058290 B1 KR 101058290B1 KR 1020080001479 A KR1020080001479 A KR 1020080001479A KR 20080001479 A KR20080001479 A KR 20080001479A KR 101058290 B1 KR101058290 B1 KR 101058290B1
Authority
KR
South Korea
Prior art keywords
exendin
insulin secreting
immunoglobulin
group
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020080001479A
Other languages
English (en)
Korean (ko)
Other versions
KR20080064750A (ko
Inventor
송대해
임창기
송태헌
김영훈
권세창
이관순
정성엽
최인영
Original Assignee
한미홀딩스 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한미홀딩스 주식회사 filed Critical 한미홀딩스 주식회사
Priority to TW097107631A priority Critical patent/TWI413528B/zh
Priority to ARP080100947A priority patent/AR065639A1/es
Publication of KR20080064750A publication Critical patent/KR20080064750A/ko
Application granted granted Critical
Publication of KR101058290B1 publication Critical patent/KR101058290B1/ko
Priority to ARP180100182A priority patent/AR110853A2/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020080001479A 2007-01-05 2008-01-04 면역글로불린 단편을 이용한 인슐린분비 펩타이드 약물결합체 Active KR101058290B1 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TW097107631A TWI413528B (zh) 2007-01-05 2008-03-05 使用免疫球蛋白片段的促胰島素複合物
ARP080100947A AR065639A1 (es) 2007-01-05 2008-03-07 Un complejo insulinotropico que utiliza un fragmento inmunogloblina
ARP180100182A AR110853A2 (es) 2007-01-05 2018-01-26 Un método para preparar el conjugado de péptido insulinotrópico, y una composición farmacéutica que comprende a dicho conjugado de péptido insulinotrópico

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020070001662 2007-01-05
KR20070001662 2007-01-05

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020100047019A Division KR101058315B1 (ko) 2007-01-05 2010-05-19 면역글로불린 단편을 이용한 인슐린분비 펩타이드 약물 결합체
KR1020110065014A Division KR20110092253A (ko) 2007-01-05 2011-06-30 면역글로불린 단편을 이용한 인슐린분비 펩타이드 약물 결합체

Publications (2)

Publication Number Publication Date
KR20080064750A KR20080064750A (ko) 2008-07-09
KR101058290B1 true KR101058290B1 (ko) 2011-08-22

Family

ID=39588830

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020080001479A Active KR101058290B1 (ko) 2007-01-05 2008-01-04 면역글로불린 단편을 이용한 인슐린분비 펩타이드 약물결합체
KR1020100047019A Active KR101058315B1 (ko) 2007-01-05 2010-05-19 면역글로불린 단편을 이용한 인슐린분비 펩타이드 약물 결합체
KR1020110065014A Ceased KR20110092253A (ko) 2007-01-05 2011-06-30 면역글로불린 단편을 이용한 인슐린분비 펩타이드 약물 결합체

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020100047019A Active KR101058315B1 (ko) 2007-01-05 2010-05-19 면역글로불린 단편을 이용한 인슐린분비 펩타이드 약물 결합체
KR1020110065014A Ceased KR20110092253A (ko) 2007-01-05 2011-06-30 면역글로불린 단편을 이용한 인슐린분비 펩타이드 약물 결합체

Country Status (20)

Country Link
US (1) US8476230B2 (https=)
EP (1) EP2114438B8 (https=)
JP (2) JP2008169195A (https=)
KR (3) KR101058290B1 (https=)
CN (3) CN103435699B (https=)
AR (2) AR065639A1 (https=)
AU (1) AU2008203574B2 (https=)
BR (1) BRPI0806262A2 (https=)
CA (1) CA2674538C (https=)
DK (1) DK2114438T3 (https=)
ES (1) ES2394121T3 (https=)
IL (1) IL199566A (https=)
MX (1) MX2009007267A (https=)
MY (1) MY164479A (https=)
NZ (1) NZ577812A (https=)
PT (1) PT2114438E (https=)
RU (1) RU2436589C2 (https=)
TW (1) TWI413528B (https=)
WO (1) WO2008082274A1 (https=)
ZA (1) ZA200904337B (https=)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014017849A1 (en) 2012-07-25 2014-01-30 Hanmi Pharm. Co., Ltd. A liquid formulation of long-acting insulin and insulinotropic peptide
WO2015183054A1 (en) 2014-05-30 2015-12-03 Hanmi Pharm. Co., Ltd. Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist
WO2015186988A1 (en) 2014-06-05 2015-12-10 Hanmi Pharm. Co., Ltd. Method for decreasing immunogenicity of protein and peptide
US9801950B2 (en) 2012-07-25 2017-10-31 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
US10017557B2 (en) 2015-08-28 2018-07-10 Hanmi Pharm. Co., Ltd. Insulin analogs and use thereof
WO2018169282A2 (ko) 2017-03-17 2018-09-20 고려대학교 산학협력단 Atpif1을 함유하는 당뇨 치료용 약학조성물
US10159715B2 (en) 2014-05-29 2018-12-25 Hanmi Pharm. Co., Ltd Method for treating diabetes comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate
WO2019066603A1 (ko) 2017-09-29 2019-04-04 한미약품 주식회사 효력이 향상된 지속성 단백질 결합체
US10253082B2 (en) 2014-01-20 2019-04-09 Hanmi Pharm. Co., Ltd Long-acting insulin and use thereof
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
EP3656792A1 (en) 2011-12-30 2020-05-27 Hanmi Science Co., Ltd. Immunoglobulin fc variants
US11396534B2 (en) 2016-09-23 2022-07-26 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
US11752216B2 (en) 2017-03-23 2023-09-12 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US8110665B2 (en) * 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
UA101670C2 (ru) * 2008-07-23 2013-04-25 Ханми Сайенс Ко., Лтд. Полипептидный комплекс, содержащий непептидильный полимер, который имеет три функциональных конца
WO2010118384A2 (en) 2009-04-10 2010-10-14 Amylin Pharmaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
WO2011107990A1 (en) * 2010-03-02 2011-09-09 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
AU2010321587A1 (en) 2009-11-23 2012-06-07 Amylin Pharmaceuticals, Inc. Polypeptide Conjugate
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
KR101324828B1 (ko) * 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
WO2012050923A2 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
JP2014521594A (ja) * 2011-05-25 2014-08-28 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 長持続期間デュアルホルモンコンジュゲート
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
PE20240686A1 (es) 2011-06-10 2024-04-10 Hanmi Science Co Ltd Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1)
PE20230404A1 (es) 2011-06-17 2023-03-07 Hanmi Science Co Ltd Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
ES2732475T3 (es) 2011-07-08 2019-11-22 Aegerion Pharmaceuticals Inc Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
CN103172745A (zh) * 2011-12-21 2013-06-26 北京韩美药品有限公司 包含免疫球蛋白Fc片段的长效人内皮抑素
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
KR101665009B1 (ko) * 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
PE20151421A1 (es) 2012-11-06 2015-09-24 Hanmi Pharm Ind Co Ltd Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
KR20140088837A (ko) * 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
TWI708782B (zh) * 2013-02-26 2020-11-01 南韓商韓美藥品股份有限公司 新穎胰島素類似物及其用途
KR101895634B1 (ko) * 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
AR096891A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
AR096890A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
AU2015242657B2 (en) * 2014-03-31 2020-05-21 Hanmi Pharm. Co., Ltd. Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
US10046058B2 (en) * 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
MY185334A (en) 2014-12-30 2021-05-06 Hanmi Pharm Ind Co Ltd Glucagon derivatives with improved stability
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
EA201890058A1 (ru) * 2015-06-30 2018-07-31 Ханми Фарм. Ко., Лтд. Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного
WO2017052329A1 (en) * 2015-09-24 2017-03-30 Hanmi Pharm. Co., Ltd. Protein complex by use of a specific site of an immunoglobulin fragment for linkage
WO2017116204A1 (ko) 2015-12-31 2017-07-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
KR102005457B1 (ko) 2016-06-29 2019-07-30 한미약품 주식회사 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
CN110291103A (zh) 2016-12-05 2019-09-27 韩美药品株式会社 具有弱化的免疫应答的缀合物
JP2020506932A (ja) * 2017-02-03 2020-03-05 ハンミ ファーマシューティカル カンパニー リミテッド 持続性が増加した生理活性物質の結合体及びその用途
BR112020002871A2 (pt) 2017-08-15 2020-07-28 Kindred Biosciences, Inc. variantes fc de igg para uso veterinário
CA3084326A1 (en) * 2017-09-28 2019-04-04 Jaehyuk Choi Long-acting conjugates of glp-2 derivatives
EP4321170A4 (en) * 2021-04-09 2025-07-16 Hanmi Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CHRONIC KIDNEY DISEASE CONTAINING A GLUCAGON DERIVATIVE
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
KR20230000682A (ko) 2021-06-25 2023-01-03 한미약품 주식회사 심혈관 질환 또는 신장 기능장애 발생의 위험을 감소시키기 위한 에페글레나타이드

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401716A (en) * 1987-04-15 1995-03-28 Semiconductor Energy Laboratory Co., Ltd. Method for manufacturing superconducting patterns
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5424686A (en) 1994-04-20 1995-06-13 Philips Electronics North America Corporation Negative-resistance-compensated microwave buffer
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US7157555B1 (en) * 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6815203B1 (en) * 1999-06-23 2004-11-09 Joslin Diabetes Center, Inc. Methods of making pancreatic islet cells
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
BR0116024A (pt) 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
US7189830B2 (en) 2001-02-19 2007-03-13 Merck Patent Gmbh Anti-KSA/IL-2 fusion proteins with reduced immunogenicity
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
EP1605897B1 (en) * 2003-03-19 2012-07-25 Eli Lilly And Company Polyethelene glycol link glp-1 compounds
MXPA05013565A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
DE10352479A1 (de) * 2003-11-07 2005-06-09 Basf Ag Verfahren zur Herstellung von Polymerisatpulvern aus wässrigen Polymerisatdispersionen
ATE555133T1 (de) * 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
JP2006514649A (ja) * 2003-12-17 2006-05-11 アミリン・ファーマシューティカルズ，インコーポレイテッド 腎症の治療および予防のための組成物
JP2007537142A (ja) 2003-12-18 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ アルブミン様物質に結合した新規のｇｌｐ−１類似物
JP2008507280A (ja) * 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
EA011166B1 (ru) 2004-12-22 2009-02-27 Эли Лилли Энд Компани Композиции слитых белков-аналогов glp-1
WO2006076471A2 (en) 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
PT1881850E (pt) 2005-05-13 2010-11-26 Lilly Co Eli Compostos peguilados de glp-1

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3656792A1 (en) 2011-12-30 2020-05-27 Hanmi Science Co., Ltd. Immunoglobulin fc variants
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
US9801950B2 (en) 2012-07-25 2017-10-31 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
US9833516B2 (en) 2012-07-25 2017-12-05 Hanmi Pharm. Co., Ltd Liquid formulation of long-acting insulin and insulinotropic peptide
WO2014017849A1 (en) 2012-07-25 2014-01-30 Hanmi Pharm. Co., Ltd. A liquid formulation of long-acting insulin and insulinotropic peptide
US10253082B2 (en) 2014-01-20 2019-04-09 Hanmi Pharm. Co., Ltd Long-acting insulin and use thereof
US10159715B2 (en) 2014-05-29 2018-12-25 Hanmi Pharm. Co., Ltd Method for treating diabetes comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate
US10188703B2 (en) 2014-05-30 2019-01-29 Hanmi Pharm. Co., Ltd. Method for treating diabetes mellitus by a composition comprising insulin and a GLP-1/glucagon dual agonist
WO2015183054A1 (en) 2014-05-30 2015-12-03 Hanmi Pharm. Co., Ltd. Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist
AU2015268199B2 (en) * 2014-05-30 2020-12-10 Hanmi Pharm. Co., Ltd. Composition for treating diabetes mellitus comprising insulin and a GLP-1/glucagon dual agonist
WO2015186988A1 (en) 2014-06-05 2015-12-10 Hanmi Pharm. Co., Ltd. Method for decreasing immunogenicity of protein and peptide
EP4219565A1 (en) 2014-06-05 2023-08-02 Hanmi Pharm. Co., Ltd. Method for decreasing immunogenicity of protein and peptide
US10017557B2 (en) 2015-08-28 2018-07-10 Hanmi Pharm. Co., Ltd. Insulin analogs and use thereof
US10647753B2 (en) 2015-08-28 2020-05-12 Hanmi Pharm. Co., Ltd. Insulin analogs and use thereof
US11396534B2 (en) 2016-09-23 2022-07-26 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
WO2018169282A2 (ko) 2017-03-17 2018-09-20 고려대학교 산학협력단 Atpif1을 함유하는 당뇨 치료용 약학조성물
US10946060B2 (en) 2017-03-17 2021-03-16 Korea University Research And Business Foundation Pharmaceutical composition containing ATPIF1 for treatment of diabetes
US11752216B2 (en) 2017-03-23 2023-09-12 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
WO2019066603A1 (ko) 2017-09-29 2019-04-04 한미약품 주식회사 효력이 향상된 지속성 단백질 결합체

Also Published As

Publication number Publication date
CA2674538A1 (en) 2008-07-10
CN101646451A (zh) 2010-02-10
BRPI0806262A2 (pt) 2011-08-30
JP2008169195A (ja) 2008-07-24
TWI413528B (zh) 2013-11-01
CN103435700B (zh) 2015-12-23
EP2114438B1 (en) 2012-08-29
CN103435700A (zh) 2013-12-11
EP2114438A1 (en) 2009-11-11
US20100105877A1 (en) 2010-04-29
RU2436589C2 (ru) 2011-12-20
CN101646451B (zh) 2014-03-26
MX2009007267A (es) 2009-11-11
AU2008203574B2 (en) 2011-12-01
DK2114438T3 (da) 2012-12-17
IL199566A (en) 2016-09-29
ES2394121T3 (es) 2013-01-21
HK1136504A1 (en) 2010-07-02
ZA200904337B (en) 2010-10-27
MY164479A (en) 2017-12-29
EP2114438B8 (en) 2012-10-03
JP5399265B2 (ja) 2014-01-29
KR101058315B1 (ko) 2011-08-22
CN103435699A (zh) 2013-12-11
KR20080064750A (ko) 2008-07-09
US8476230B2 (en) 2013-07-02
AR110853A2 (es) 2019-05-08
AU2008203574A1 (en) 2008-07-10
KR20110092253A (ko) 2011-08-17
PT2114438E (pt) 2012-10-11
CA2674538C (en) 2013-12-17
TW200930408A (en) 2009-07-16
CN103435699B (zh) 2015-04-15
KR20100061786A (ko) 2010-06-09
EP2114438A4 (en) 2010-09-01
JP2010515677A (ja) 2010-05-13
AR065639A1 (es) 2009-06-17
RU2009129953A (ru) 2011-02-10
NZ577812A (en) 2012-01-12
WO2008082274A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
KR101058290B1 (ko) 면역글로불린 단편을 이용한 인슐린분비 펩타이드 약물결합체
KR101424550B1 (ko) 지속형 인슐린 결합체 및 지속형 인슐린 분비 펩타이드 결합체를 포함하는 당뇨병 치료용 조성물
US20080124347A1 (en) Insulinotropic peptide conjugate using carrier substance
KR101382593B1 (ko) 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
KR101135244B1 (ko) 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
TWI388570B (zh) 包含具有三個官能端的非肽醯聚合物的多肽複合物
US20090238838A1 (en) Insulinotropic peptide conjugate using an immunoglobulin fc
KR20080098216A (ko) 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
JP6336394B2 (ja) 生理活性ポリペプチド複合体の製造方法
KR20110134210A (ko) 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체
KR20120043205A (ko) 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드?２（ｇｌｐ?２）약물 결합체
KR20120043208A (ko) 항 비만 펩타이드의 지속형 결합체
KR101974305B1 (ko) 생리활성 폴리펩타이드 결합체 제조 방법
KR20170100908A (ko) 지속형 fgf21 수용체 아고니스트 결합체 및 지속형 인슐린 분비 펩타이드 결합체를 포함하는 대사증후군 치료용 조성물
HK1136504B (en) An insulinotropic complex using an immunoglobulin fragment
KR20190062332A (ko) 생리활성 폴리펩타이드 결합체 제조 방법
KR20170005179A (ko) 생리활성 폴리펩타이드 결합체 제조 방법

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20080104

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20091119

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0107 Divisional application

Comment text: Divisional Application of Patent

Patent event date: 20100519

Patent event code: PA01071R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20101229

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0107 Divisional application

Comment text: Divisional Application of Patent

Patent event date: 20110630

Patent event code: PA01071R01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20110801

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20110812

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20110812

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20140620

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20140620

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20150615

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20150615

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20160720

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20160720

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20170719

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20170719

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20180718

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20180718

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20190718

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20190718

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20200715

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20210510

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20230615

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20240617

Start annual number: 14

End annual number: 14

PR1001 Payment of annual fee

Payment date: 20250617

Start annual number: 15

End annual number: 15